Suppr超能文献

血管紧张素受体-脑啡肽酶抑制剂与射血分数降低的心力衰竭中心血管生物标志物和心脏重构的关系。

Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.

机构信息

Massachusetts General Hospital, Boston (S.P.M., A.C., R.R.K., J.L.J.).

Novartis Pharmaceuticals, East Hanover, NJ (M.F.P., J.H.W., K.M.W.).

出版信息

Circ Heart Fail. 2021 Jun;14(6):e008410. doi: 10.1161/CIRCHEARTFAILURE.120.008410. Epub 2021 May 15.

Abstract

BACKGROUND

Sacubitril/valsartan (S/V) treatment is associated with reverse cardiac remodeling and reductions in biomarkers reflecting ventricular wall stress and myocardial injury, such as NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-cTnT (high-sensitivity cardiac troponin T), and soluble suppressor of tumorigenicity 2 (sST2). How longitudinal changes in these biomarkers analyzed collectively are associated with cardiac remodeling in patients with heart failure with reduced ejection fraction treated with S/V is uncertain.

METHODS

In a prospective study of S/V in patients with heart failure with reduced ejection fraction, this prespecified exploratory analysis included patients with serially collected biomarkers and echocardiographic measures of cardiac remodeling through 12 months of treatment. A multivariate latent growth curve model assessed associations between simultaneous changes in biomarkers and left ventricular ejection fraction and left atrial volume index.

RESULTS

Seven hundred fifteen out of 794 total study participants were included (mean age 65 years, 73% male). Mean baseline left ventricular ejection fraction and left atrial volume index were 29% and 40 mL/m, respectively. Adjusted geometric mean baseline concentrations for biomarkers included NT-proBNP of 649 pg/mL, hs-cTnT of 15.9 ng/L, and sST2 of 24.7 ng/mL. Following initiation of S/V, circulating concentrations of NT-proBNP, hs-cTnT, and sST2 significantly decreased within 30 days and remained significantly different than baseline at all subsequent timepoints. From baseline to month 12, decreases in adjusted biomarker concentrations averaged -27.9% (95% CI, -35.1% to -20.7%; <0.001) for NT-proBNP; -6.7% (95% CI, -8.8% to -4.7%; <0.001) for hs-cTnT; and -1.6% (95% CI, -2.9% to -0.4%; <0.001) for sST2. NT-proBNP concentrations were predictive of later changes in hs-cTnT. The magnitude of reductions in NT-proBNP and hs-cTnT concentrations associated with improvements in left ventricular ejection fraction and left atrial volume index. There was no association between changes in sST2 and changes in other measures.

CONCLUSIONS

Following initiation of S/V, NT-proBNP, hs-cTnT, and sST2 concentrations decreased significantly. Longitudinal changes in NT-proBNP and hs-cTnT together associated with left atrial and left ventricular reverse remodeling. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02887183.

摘要

背景

沙库巴曲缬沙坦(S/V)治疗与心脏逆向重构以及反映心室壁压力和心肌损伤的生物标志物的降低有关,如 NT-proBNP(氨基末端 B 型利钠肽前体)、hs-cTnT(高敏心肌肌钙蛋白 T)和可溶性肿瘤抑制物 2(sST2)。目前尚不清楚 S/V 治疗射血分数降低的心力衰竭患者中,这些生物标志物的纵向变化与心脏重构之间的关系。

方法

在 S/V 治疗射血分数降低的心力衰竭患者的前瞻性研究中,这项预先指定的探索性分析纳入了在 12 个月治疗期间连续采集生物标志物和心脏重构超声心动图测量值的患者。采用多变量潜在增长曲线模型评估生物标志物同时变化与左心室射血分数和左心房容积指数之间的关联。

结果

在总共 794 名研究参与者中,715 名(平均年龄 65 岁,73%为男性)被纳入分析。平均基线左心室射血分数和左心房容积指数分别为 29%和 40ml/m。纳入生物标志物的调整后的几何平均基线浓度包括 NT-proBNP 为 649pg/ml、hs-cTnT 为 15.9ng/L 和 sST2 为 24.7ng/ml。S/V 治疗开始后,NT-proBNP、hs-cTnT 和 sST2 的循环浓度在 30 天内显著降低,并且在所有后续时间点均显著低于基线。从基线到第 12 个月,调整后的生物标志物浓度的平均降低幅度分别为 NT-proBNP 为-27.9%(95%CI:-35.1%至-20.7%;<0.001);hs-cTnT 为-6.7%(95%CI:-8.8%至-4.7%;<0.001);sST2 为-1.6%(95%CI:-2.9%至-0.4%;<0.001)。NT-proBNP 浓度可预测 hs-cTnT 的后续变化。NT-proBNP 和 hs-cTnT 浓度的降低幅度与左心室射血分数和左心房容积指数的改善相关。sST2 浓度的变化与其他测量值的变化之间无关联。

结论

S/V 治疗开始后,NT-proBNP、hs-cTnT 和 sST2 浓度显著降低。NT-proBNP 和 hs-cTnT 的纵向变化与左心房和左心室的逆向重构相关。注册:网址:https://www.clinicaltrials.gov;唯一标识符:NCT02887183。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验